The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of a nationwide genomic screening network for squamous cell lung cancer in Japan (LC-SCRUM-Japan).
 
Tadasuke Shimokawaji
No Relationships to Disclose
 
Eri Sugiyama
No Relationships to Disclose
 
Shingo Matsumoto
Honoraria - Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly Japan (Inst); Novartis (Inst); Takeda (Inst)
 
Masato Shingyoji
No Relationships to Disclose
 
Kadoaki Ohashi
No Relationships to Disclose
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Nippon Boehringer Ingelheim; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Hiromi Aono
No Relationships to Disclose
 
Yuichiro Ohe
Employment - Chugai Pharma (I)
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyorin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - AstraZeneca
 
Shunichi Sugawara
Honoraria - AstraZeneca; Chugai Pharma; Nippon Boehringer Ingelheim
 
Naoki Furuya
No Relationships to Disclose
 
Hirofumi Nakazaki
No Relationships to Disclose
 
Kageaki Taima
No Relationships to Disclose
 
Hiroshi Watanabe
No Relationships to Disclose
 
Taishi Harada
No Relationships to Disclose
 
Tomohiro Sakamoto
No Relationships to Disclose
 
Shinnosuke Ikemura
No Relationships to Disclose
 
Katsuya Tsuchihara
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Eisai; Merck Serono; Takeda
 
Koichi Goto
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda